MEDICINA
Departamento
VU University Medical Center
Ámsterdam, HolandaPublicaciones en colaboración con investigadores/as de VU University Medical Center (38)
2024
2023
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 27-50
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
-
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet
Cytometry Part B - Clinical Cytometry
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
2020
-
Core outcome set measurement for future clinical trials in acute myeloid leukemia: The HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting
Trials, Vol. 21, Núm. 1
-
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
ESMO Open, Vol. 5, Núm. 1
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936
-
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Haematologica, Vol. 104, Núm. 10, pp. 1935-1949
2018
-
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Critical Reviews in Oncology/Hematology, Vol. 121, pp. 74-89
-
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial
Journal of Clinical Oncology
-
Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network
Leukemia, Vol. 32, Núm. 7, pp. 1542-1560
2017
-
Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study
International Journal of Molecular Sciences, Vol. 18, Núm. 4
-
High-dose therapy and autologous stem cell transplantation in patients with poems syndrome: A retrospective study of the plasma cell disorder sub-committee of the chronic malignancy working party of the European society for blood & marrow transplantation
Haematologica, Vol. 102, Núm. 1, pp. 160-167
-
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group
Haematologica, Vol. 102, Núm. 2, pp. 308-319